Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response does not contain substantive label claims; therefore there is no measurable alignment or contradiction with the provided FDA boxed warning (all-cause mortality).
Category Scores
Accurate Statements
No statement in the AI response addresses TYGACIL’s boxed warning language (all-cause mortality risk difference 0.6%) or the label’s “reserved for use” limitation directly.
Not applicable—no mortality/boxed-warning claims were made in the response.
Unsupported Statements
All the listed microbiology/combination-therapy claims (e.g., MIC fold-changes, synergy percentages, mechanisms, resistance targets), and safety claims about nausea/nephrotoxicity for specific combination partners, are not supported by the provided FDA label excerpts.
The supplied prescribing information only includes excerpts on boxed warning/all-cause mortality, limitations of use (not indicated for HAP/VAP), and limited mortality/pneumonia efficacy details; it does not provide any information validating these combination-therapy efficacy/mechanism or nausea/nephrotoxicity statements.
“No FDA-approved tigecycline combos exist.”
The provided label excerpts do not state whether any tigecycline combination regimens are FDA-approved.
“Use of tigecycline combinations is off-label.”
The provided label excerpts do not address approval status of combination regimens; only the drug’s own indication limitations are provided.
Contradictions
Important Omissions
The specific boxed warning claim that TYGACIL-treated patients have an observed increase in all-cause mortality vs comparator (adjusted risk difference 0.6%, 95% CI 0.1–1.2) and that the cause is not established, plus the “should be reserved for use when alternative treatments are not suitable” language.
Importance:
High
Limitations of use for hospital-acquired/ventilator-associated pneumonia (not indicated; greater mortality and decreased efficacy reported in a comparative clinical trial) and the ventilator-associated pneumonia mortality/cure details referenced in the label excerpt.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
No on-label boxed-warning mortality figures or reserved-use guidance were provided in the response. However, no direct contradiction to the provided boxed-warning text appears because the response does not discuss it.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The response does not address the FDA boxed warning all-cause mortality content provided in the prompt and includes multiple unsupported claims unrelated to the supplied label excerpts.
Suggested Improvement
Replace/limit the response to the provided label excerpts on boxed warning (all-cause mortality risk difference 0.6%, cause not established, reserved-use language) and the label’s limitations of use regarding HAP/VAP. Do not add combination-therapy efficacy/safety and approval-status claims unless supported by the provided prescribing information.